Ticagrelor vs Clopidogrel Effect on MFR in CAD Population
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
Ticagrelor is one of 3 anti-platelet medications used in patients with acute coronary
syndrome (ACS) to prevent further clot formation and further ischemic damage to myocardial
tissue. Overall benefits of one drug over the other is neutral in this generally unstable
population. In pre-clinical trials, ticagrelor showed secondary effects, involving the
release of adenosine to heart muscle where the demand for blood was increased due to a stress
condition. Blood flow was increased, potentially preventing potential damage.
This study will compare ticagrelor, currently only approved for use in ACS patients, against
clopidogrel by measuring the myocardial blood flow(MBF) during stress to validate this
phenomenon. The effect on blood flow will be measurable by using two specific doses of
adenosine as the pharmacologic stress and correlating with measurements of blood flow using
positron emission tomography (PET) nuclear imaging.
This study hypothesizes that the increase in MBF during intermediate dose adenosine infusion
will be greater in ticagrelor treated subjects compared to clopidogrel treated subjects